Markets & Regulations

(Image: Getty/Radachynskyi)

Recro spins out Baudax to boost CDMO focus

By Vassia Barba

Recro Pharma announces the separation of its acute care business to launch Baudax Bio as a developer of products, including non-opioid analgesics, to concentrate on its CDMO business.

(Image: Getty/DenKuvaiev)

The next act: ACRO, R&D Caucus moving forward with second Cures bill

By Melissa Fassbender

ACRO is collaborating with the Congressional Research and Development Caucus and others to bring forth a new Cures bill focused, in part, on patient engagement, data, and digital health – with draft legislation anticipated early next year.